InnoHeart Medical Completes Over RMB 200 Million Series B Strategic Financing, Focused on Iron-Based Bioresorbable Stents

Intelligent Finance APP learned that, according to the WeChat Official Account of "Biotyx Medical (Shenzhen) Co., Ltd.", Biotyx Medical (Shenzhen) Co., Ltd. (hereinafter referred to as "Biotyx Medical") has successfully completed a B-round strategic financing of over 200 million yuan. This round of financing introduced several strategic investors, including Gongqingcheng Huayi Private Equity Fund Management Co., Ltd. and Guangfa Qianhe Investment Co., Ltd. The Series A investors, IDG Capital and Shanghai Baoquan, continued their investment. The B-round capital increase agreement and shareholder agreement have now been signed. Investors in this round of financing will collectively invest more than 200 million yuan into Biotyx Medical as per the terms of the capital increase agreement.

According to publicly available data, Biotyx Medical is the world's only enterprise engaged in the research and development of iron-based bioresorbable scaffolds. With advanced scientific research conditions and a high-level R&D team, it is committed to developing innovative interventional medical device products to serve a wide range of patients and address unmet clinical needs globally. It has successfully developed multiple fully degradable iron-based bioresorbable scaffold products, which are applied in several mainstream fields such as coronary heart disease, pediatric pulmonary artery stenosis, and infrapopliteal artery stenosis.